Just one year after the UK government published its Life Science Vision, outlining the ambitions of the government and the life science sector for the next 10 years, the Association of the British Pharmaceutical Industry (ABPI) has appointed a new president who will take on the plan.
The Association of the British Pharmaceutical Industry (ABPI) has chosen Pinder Sahota, General Manager and Corporate Vice President of Novo Nordisk UK as its new President.
Sahota will be taking over from Ben Osborn of Pfizer and will continue to oversee the ABPI, the ABPI Board, and the ABPI’s Code of Practice, which is administered by the Prescription Medicines Code of Practice Authority (PMCPA).
This appointment comes just one year after the UK government’s publication of the Life Sciences Vision, which sets forth the government and the life science sector’s ambitions for the next decade. According to ABPI, ensuring the plans set forth in the new vision become a reality will be central to Sahota’s presidency. He will be working closely with the government to support the UK’s National Health Service (NHS) and make sure that patients receive the innovative medicines they need.
Sahota, previously Vice President of the ABPI, is the UK General Manager of Novo Nordisk. He also chairs the CBI’s Health Council and has previously served as Vice Chair of the European Medicines Group.
“The past two years have demonstrated just how important medicines and vaccines are to our way of life. Improving how we use new medicines can now support the NHS to recover from the pandemic by addressing the significant variations which currently exist in care across the country.”